NIH Clinician Sought Retatrutide for 79-Year-Old Patient as Trump Speculation Swirls
Updated
Updated · thenewworld.co.uk · Jun 23
NIH Clinician Sought Retatrutide for 79-Year-Old Patient as Trump Speculation Swirls
3 articles · Updated · thenewworld.co.uk · Jun 23
Summary
Stat News reported that NIH clinician Ranganath Muniyappa asked the FDA and Eli Lilly in April for compassionate-use access to experimental obesity drug Retatrutide for a 79-year-old patient.
The request cited refractory obesity, obstructive sleep apnea and pulmonary hypertension — conditions that can qualify as serious or life-threatening under the FDA pathway for unapproved treatments.
Three anonymous sources said the application drew interest from top health officials, but Stat said it could not confirm the patient's identity.
White House spokesperson Kush Desai pointed to Trump's latest medical memo when asked whether the patient was the president, though the memo does not mention sleep apnea or pulmonary hypertension.
Retatrutide is still unapproved in the US, despite trial results that have fueled expectations for a potent new obesity and diabetes treatment.
With 'bariatric surgery in a shot' coming, can regulators prevent a global black market from emerging?
Does one man's early access to a 'miracle' drug reveal a two-tiered system for American healthcare?
Compassionate Use Controversy: Eli Lilly’s Retatrutide Granted to 79-Year-Old Patient Raises Questions on Fairness and FDA Policy
Overview
In April 2026, Eli Lilly granted a 79-year-old man access to its experimental weight loss drug, retatrutide, through the FDA’s compassionate use pathway after he experienced only moderate results with another Eli Lilly obesity drug. This unusual approval, revealed in June 2026, sparked controversy because compassionate use is rarely applied to obesity, a widespread but not typically life-threatening condition. Experts questioned why a single patient received special access, raising concerns about fairness and transparency. The case highlights ethical debates and may set a precedent for future requests, as public interest in powerful new obesity treatments continues to grow.